Therapeutic protein silencing reduces the likelihood of liver failure in older transplant donors

by CIC bioGUNE

3 years ago
Hepatic ischaemia-reperfusion, ransplant, Liver Disease

Hepatic ischaemia-reperfusion injury is the leading cause of early organ failure after transplant. MCJ protein silencing emerges as a new therapy to prevent liver failure after ischaemia-reperfusion ...

IDIBELL participates in a study aimed to reduce the likelihood of liver failure in older transplant donors

by Hospital Universitari de Bellvitge

3 years ago
Liver transplant, transplant, liver disease

Liver transplant is the only curative treatment for acute liver failure and end-stage liver disease. Since its main limitation is the scarcity of available organs, a major effort has been made in rece...

Alterations in serum magnesium levels are presented as a new risk factor in liver disease

by CIC bioGUNE

3 years ago
liver disease, serum magnesium levels, fatty liver, nutritional habits

Individuals with alterations in magnesium levels have an increased risk of presenting fatty liver disease with inflammation and fibrosis, as concluded by a study that has just been published in Journa...

A European study with participation from Lleida identifies a possible target to combat nonalcoholic fatty liver

by IRB Lleida. Institut de Recerca Biomèdica

5 years ago
Non-alcoholic fatty liver, cirrhosis, cancer, simple steatosis, protein mitofusin 2, liver disease

The research concludes that the protein mitofusin 2 (Mfn2) is a factor that protects against this disease

IDIBAPS-Clínic: The Group of inflammation in liver disease receives an award for research on albumin

by Fundació Clínic per a la Recerca Biomèdica

8 years ago
Albus awards, Joan Clària, liver disease, albumin, Grifols

Joan Clària, head of the Inflammation on liver disease research group at IDIBAPS-Clínic, has been one of the winners of the Albus awards, given annually by the company Grifols. With an endowment of ...

Cerium oxide nanoparticles may be of therapeutic value in chronic liver disease

by Vall d’Hebron

8 years ago
Cerium oxide nanoparticles, liver disease, CeO2NPs

Dr. Victor Puntes, head of the Design and Pharmacodynamics of Nanoparticles group at the CIBBIM- Nanomedicine, has recently published in the Journal of Hepatology a study about the benefits of cerium ...